Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/164572
Full metadata record
DC FieldValueLanguage
dc.creatorLaza-Vásquez, C-
dc.creatorRué-Monné, M-
dc.creatorFougo, JL-
dc.creatorPeleteiro, B-
dc.date.accessioned2025-01-08T17:17:02Z-
dc.date.available2025-01-08T17:17:02Z-
dc.date.issued2024-
dc.identifier.issn1473-5709-
dc.identifier.issn0959-8278-
dc.identifier.urihttps://hdl.handle.net/10216/164572-
dc.description.abstractObjectives The success of a breast cancer screening program is highly dependent on adherence. We aimed to compare the differential effect of participation in breast cancer screening program versus opportunistic screening or symptomatic detection on tumour characteristics. Methods We included women referred to our Breast Centre in 2015–2021: 321 from the breast cancer screening group (group 1) and 422 through opportunistic screening or due to symptomatic detection (group 2). We compared data on sociodemographics, breast cancer detection, clinical features and tumour characteristics. Results A total of 10.6% of women in group 1 had breast symptoms and 63.8% had breast signs, with group 2 presenting higher proportions (57.6 and 77.8%, respectively, P < 0.001). The median tumour size in group 1 was smaller compared with group 2 (14 vs 17 mm, P < 0.001). A total of 8.7% of women in group 1 had nodal involvement whereas in group 2 the proportion corresponded to 19.0% (P < 0.001). No women in group 1 were diagnosed with metastasis, while metastases were found in 2.4% of those from group 2 (P = 0.005). There were no significant differences in molecular subtype of invasive tumours between the two groups. Conclusion The tumour characteristics of women who participated in the breast cancer screening program showed in almost all characteristics more favourable results in comparison with the group who underwent opportunistic screening or sought care due to symptoms. The lower clinical stage observed in those referred from the organised program reaffirms that it is an effective measure for early detection, diagnosis, and treatment. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.pt_PT
dc.description.sponsorshipThis work is financed by national funds through the FCT \u2013 Foundation for Science and Technology, I.P., within the scope of projects UIDB/04750/2020 and LA/P/0064/2020. The first author received a grant from Santander Program scholarship 2020 as a predoctoral fellow at the Santander Foundation and University of Lleida, Spain.pt_PT
dc.language.isoengpt_PT
dc.publisherLippincott, Williams & Wilkinspt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04750/2020/PTpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA/P/0064/2020/PTpt_PT
dc.relation.ispartofEur J Cancer Prev. 2024 Aug 13. doi: 10.1097/CEJ.0000000000000919. Online ahead of print.-
dc.rightsrestrictedAccesspt_PT
dc.titleComparison of the differential effect of participation in breast cancer screening program versus opportunistic screening or symptomatic detection on tumour characteristicspt_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Saúde Públicapt_PT
dc.identifier.doi10.1097/CEJ.0000000000000919-
dc.relation.publisherversionhttps://journals.lww.com/eurjcancerprev/abstract/9900/comparison_of_the_differential_effect_of.168.aspx-
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
lazavasquez2024.pdf
  Restricted Access
641.9 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.